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Abstract 
Breast cancer is the most commonly diagnosed malignancy in women worldwide. 
Recently, uncontrolled expression of microRNAs was detected in several human disorders like 
cardiovascular, neurological, intestinal and autoimmunity diseases. MicroRNAs (miRNAs) are 
now investigated as novel prognostic and diagnostic biomarkers for several solid tumors like 
breast, lung, and gastrointestinal cancers. Current data suggest that miRNAs are implicated in 
various oncogenic processes implicated in breast cancer carcinogenesis trough modulating 
canonical Wnt pathway. Aberrant activation of Wnt/b-catenin signaling was shown to be 
significantly associated with tumor progression and poor prognosis in patients with breast cancer. 
This review presents recent findings on the molecular mechanism of microRNAs in regulation of 
Wnt/β-catenin signaling involved in tumorigenesis of breast cancer. 
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1. Introduction  
 
Breast cancer ranks as the most prevalent malignancy around the world and the second 
reason of cancer related death in female population [1]. Despite great improvements in screening, 
diagnosis and therapeutic strategies, the prognosis and survival outcomes in patients with breast 
cancer are still unsatisfying [2]. Therefore, it is clinically desirable to identify novel prognostic 
markers in breast cancer. Recent studies revealed that breast cancer as a heterogeneous disease 
can be divided into several molecular subtypes with different pathological features and clinical 
responses [3, 4]. The breast cancer tumorigenesis was recognized as a multistep process which 
is modulated by various oncogenic cell signaling cascades including PI3K/AKT and Wnt/b-catenin 
pathways [5-9]. For instance, upregulation of b-catenin and its downstream targets were shown 
to be significantly related to malignant features and poor clinical outcomes in patients with breast 
cancer [10, 11]. Recent molecular investigations to identify novel mechanisms involved in breast 
cancer tumorigenesis indicate that some miRNAs were upregulated along cancer development 
leading to aberrant activation of various oncogenic signaling pathways. 
MicroRNAs (miRNAs) are endogenous, small non-coding RNAs, that are involved in 
regulating gene expression by pairing with 3'-untranslated regions in target mRNAs. Aberrant 
expression of multiple miRNAs is considered to have critical roles in controlling various biological 
events like cell differentiation, metabolism, proliferation, tumorigenesis and drug resistance [12-
14]. Regarding their target genes, miRNAs can act as tumor-suppressors or oncogenes in 
modulating intracellular signalings events. It is well stablished that the over-expressed miRNAs 
have prominent effects on tumor cell growth and progression by activating multiple oncogenic 
signalings like Wnt/β-catenin pathway [15, 16]. The oncogenic activity of these miRNAs is 
mediated by targeting several tumor suppressors including GSK-3 β, APC and PTEN resulted in 
tumor growth and metastasis in breast cancer patients. Conversely, the tumor suppressor 
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miRNAs were shown to have anti-cancer role by inhibiting tumor cell proliferation through 
suppressing β-catenin or Wnt receptors like frizzled proteins. 
The regulatory function of miRNAs on the Wnt/β-catenin signaling, suggesting a promising 
role of miRNAs in breast cancer therapy. Here we reviewed recent findings on the regulatory 
effects of miRNAs on Wnt/β-catenin signaling involved in tumorigenesis of breast cancer. 
 
2. Wnt/ β-catenin signaling pathway 
The Wnt/ β-catenin signaling plays essential roles in cancer cell growth, survival and 
metastasis [17, 18]. Generally, the intracellular Wnt signaling subdivided into β-catenin dependent 
(canonical) and β-catenin in-dependent (non-canonical) routes. The canonical Wnt/β-catenin axis 
was found to be associated with several oncogenic events including tumor cell proliferation, 
migration, EMT and invasion [18, 19]. In the condition that canonical Wnt signaling is inactivated, 
the cytoplasmic β-catenin proteins were phosphorylated by tumor suppressors glycogen synthase 
kinase 3 β (GSK-3 β) and casein kinase 1 (CK1) leading to ubiquitination and proteolysis by 
proteasomes resulted in inactivation of β-catenin signaling [20]. However, the canonical Wnt 
signaling was shown to be activated trough binding of Wnt ligand to its specific receptors including 
LRP-5/6 (LDL receptor–related protein 5 or 6) and Frizzled proteins. This in turn induces next 
components of Wnt pathway comprising disheveled resulted in deactivation of GSK-3 β and 
dissociation of β-catenin proteins from destruction complex formed by GSK-3 β, CK1, Axin, and 
APC (adenomatous polyposis coli). Therefore, β-catenin proteins accumulated in the cytosol can 
transferred to the nucleus and regulate multiple downstream genes like c-Myc and cyclin D1[21, 
22].  
Cyclins, which are considered as key promoters of cellular proliferation, have a prominent 
role in cell cycle progression through inducing cyclin dependent kinase enzymes [10, 23]. 
Nowadays, it is well-known that any defect in regulation of β-catenin target genes may causes 
un-controlled cell cycle progression and development of several types of human tumors like 
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breast, lymphoma, melanoma, colorectal, and prostate cancers [24-27]. Moreover, prolonged 
activity of Wnt/β-catenin signaling was shown to be associated with clinical poor outcomes and 
resistance to chemotherapy [28, 29]. 
 
3. Regulatory role of oncogenic miRNAs in Wnt/β-catenin signaling in breast cancer 
cells 
It is widely accepted that over-activation of Wnt/β-catenin signaling is implicated in 
tumorigenesis and progression of multiple human cancers [18]. Growing body of evidence 
indicate that downregulation of tumor suppressors involved in regulation of Wnt/β-catenin 
pathway have critical roles in breast cancer tumorigenesis. As shown in figure 1, there are various 
studies demonstrated that some miRNAs can promote Wnt signaling trough suppressing negative 
regulators such as GSK-3 β and APC [30]. Recently, miR-1229 was detected to be upregulated 
in breast tumor patients. Aberrant expression of miR-1229 induces Wnt/β-catenin signaling trough 
targeting GSK-3 β, APC and ICAT proteins [30]. ICAT also known as inhibitor of β-catenin and 
TCF (T cell factor), inhibits the expression of downstream targets of Wnt signaling by preventing 
interaction of β-catenin and TCF. The overexpression of miR-1301 was found to be associated 
with aggressive features and poor clinical outcomes in patients with breast cancer. It has been 
demonstrated that the miR-1301 can downregulates ICAT expression by directly binding to 3´-
UTR of its mRNA [31]. These data lead to considering miR-1301 as a novel prognostic biomarker 
for breast tumor. MiR-125b is another Wnt/ β-catenin signaling pathway regulatory miRNA, which 
is overexpressed in breast cancer [32]. It has been shown that the 3´-UTR of APC mRNA have 
targeted by miR-125b providing the mechanism by which miR-125b can induce Wnt/ β-catenin 
signaling by targeting APC. Downregulation of miR-125b was found to be correlated with inhibition 
of Wnt/ β-catenin signaling resulted in decreased tumor development and dissemination [32]. 
Thus, repression of miR-125b or overexpression of APC may be considered as potential 
therapeutic targets for management of breast tumors. 
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The expression of GSK-3 β protein was also found to be inhibited by miR-3646. Moreover, 
elevated levels of miR-3646 in breast cancer patients was shown to be associated with both 
docetaxel resistance and upregulation of β-catenin [33]. To further investigate the mechanism of 
miRNAs in drug resistance in breast cancer, Shen et al. demonstrated that miR-29a was 
significantly upregulated in Adriamycin-resistant MCF-7 cells [34]. Ectopic expression of miR-29a 
was observed to be related to downregulation of GSK-3 β and PTEN tumor suppressors in MCF-
7 breast cancer cells. Therefore, blockade of PTEN/GSK-3 β signaling may resulted in Adriamycin 
resistance in breast tumors. Taken together, these results indicate that miR-3646 and miR-29a 
can induce drug resistance in breast tumor cells by promoting Wnt/β-catenin signaling trough 
suppression of GSK-3 β.  
Similarly, Ma et al. indicated that miR-301 induces Wnt signaling by targeting PTEN 
(phosphatase and tensin homolog) in breast cancer cells [35]. PTEN was identified as a master 
regulator of several oncogenic pathways including PI3K/AKT and Wnt signaling which is 
downregulated in various human cancers [9, 36, 37].  
Additionally, previous findings demonstrated that certain miRNAs can induce canonical 
Wnt pathway trough targeting Wnt antagonists like Wnt inhibitory factor-1 (WIF1). WIF1 was 
shown to be repressed via miR-374a which is upregulated in patients with metastatic breast 
cancer [38]. The overexpression of miR-374a was reported to be strongly associated with tumor 
growth and reduced survival in breast cancer patients with distant metastases. To further 
elucidate the metastatic function of miR-374a, it has been found that miR-374a downregulates 
the expression of Wnt5a in breast cancer cells [38]. The Wnt5a as one of the main regulators of 
non-canonical pathway, activates CK1 leading to phosphorylation of β-catenin and consequently 
inhibition of Wnt pathway [39, 40]. These data provide evidence that the oncogenic function of 
miR-374a in inducing cancer cell metastasis can be mediated by suppressing Wnt/ β-catenin 
signaling inhibitors. To further explore whether oncogenic miRNAs can inhibit regulatory proteins 
of Wnt/ β-catenin signaling, Ren et al. reported that miR-638 is upregulated in breast cancer and 
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inhibits DACT3 as one of the main modulators of Wnt/ β-catenin pathway [41]. DACT3, a member 
of DACT family, was identified as a potent tumor suppressor which inhibits tumor cell proliferation 
by regulating β-catenin expression in various human malignancies [42]. Additionally, it has been 
reported that upregulation of miR-638 was directly correlated with malignant features of breast 
cancer while regulates cellular autophagy [41].  
In another investigation, Chen et al. demonstrated that aberrant expression of miR-373 
has prominent role in promoting EMT by inducing mesenchymal markers like β-catenin in breast 
cancer cells [43]. These results suggest that miR-373 can promote epithelial-to-mesenchymal 
transition (EMT) and metastasis in breast tumors by upregulating Wnt/ β-catenin signaling 
pathway. 
 
4. Regulatory role of tumor suppressor miRNAs in Wnt/ β-catenin signaling in breast 
cancer cells 
β-catenin as a potent oncogene is upregulated in multiple human cancers. β-catenin 
regulates expression of multiple proteins involved in cell proliferation like cyclin D1 which is found 
to be upregulated in nearly 50% of patients with breast cancer [10]. Aberrant activity of β-catenin 
was directly related to malignant manifestations and poor prognosis in breast cancer [10, 44]. β-
catenin was identified as target gene for some regulatory miRNAs including miR-26b, miR-135, 
miR-214, miR-216a, and miR-340 that are downregulated in breast tumor cells [45-49]. More 
investigations on the mechanism of miR-135 was also demonstrated that this tumor suppressor 
miRNA can inhibit tumor cell proliferation and EMT by regulating GSK3- β and matrix 
metalloproteinase (MMP) enzymes respectively [46]. Consistently, Xiong et al. reported that miR-
30a-5p represses β-catenin downstream targets like cyclin B1, cyclin D1 and c-Myc in breast 
tumor cells [50]. It has been also reported that expression of miR-30a-5p is inversely related to 
the expression of ubiquitin protein ligase E3C (UBE3C) in breast cancer cell lines. UBE3C was 
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shown to be upregulated in breast cancer leads to overexpression of c-Myc and cyclin D1 [50, 
51].  
Furthermore, miR-138 and miR-449b-5p were identified as tumor suppressor miRNAs 
which inhibit tumor progression and metastasis by targeting CREPT (Cell Cycle-Related and 
Expression-elevated Protein in Tumor) [52, 53]. The overexpression of CREPT was detected in 
breast tumor cells and tissues. CREPT as an oncogene protein, has a critical role in cellular 
proliferation trough modulating cell cycle-related genes like cyclin D1 [54, 55]. MiR-384 is another 
tumor suppressor microRNA which is downregulated in breast cancer patients [56]. Upregulation 
of miR-384 inhibits ACVR1 (Activin A receptor type 1) resulted in repression of Wnt/β-catenin axis 
in breast tumors. Previous data indicate that ACVR1 can induce tumor cell metastasis by 
promoting Wnt/β-catenin pathway in several human malignancies like breast cancer [57, 58]. 
Consistent with these findings, it has been shown that miR-30 inhibits cancer cell invasion and 
metastasis while induces cell apoptosis by repressing CTHRC1 (Collagen triple helix repeat 
containing-1) in breast tumors [59]. CTHRC1 is a secretory protein involved in stabilizing binding 
of Wnt ligand to their Frizzled receptors leading to activation of Wnt signaling pathway. Further 
studies on the oncogenic function of CTHRC1 indicate that elevated levels of CTHRC1 induces 
GSK3 β and β-catenin activities which are associated with aggressive clinicopathological 
manifestations and worse prognosis in several malignant tumors including gastrointestinal, liver, 
breast and non-small cell lung cancers [60-62]. MiR-140-5p is another Wnt inhibitory miRNA 
which is down-regulated in breast cancer stem cells. Ectopic expression of miR-140-5p 
represents anti-tumor activity mediated by targeting Wnt1 [63].  
To further investigate the inhibitory function of regulatory miRNAs on Wnt/ β-catenin axis, 
it has been reported that some miRNAs can limit tumor progression by targeting Wnt receptors 
like Frizzled proteins. For instance, Liu et al. reported that miR-224 represents anti-cancer 
properties trough targeting Frizzled 5 receptor proteins resulted in inhibition of Wnt signaling in 
breast cancer [64]. In line with this, Leu et al. demonstrated that miR-1 inhibits Frizzled 7 and 
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tankyrase 2 proteins resulted in reduced cellular proliferation and migration in breast tumors [65]. 
Similarly, Jiang et al illustrated that miR-100 which is repressed in breast cancer patients can 
inhibit Wnt/ β-catenin pathway by directly targeting Frizzled 8 receptor proteins [66]. In another 
study, the effective role of regulatory miRNAs on secreted Frizzled-related proteins (SFRPs) was 
investigated in breast tumor cells. Their results indicate that miR-27a can restrict tumor cell 
proliferation, migration and invasion by targeting SFRPs [67]. These results support the idea that 
Frizzled receptors and their related proteins may be considered as promising targets for breast 
cancer therapy.  
To further identify the oncogenic targets regulated by miRNAs, it has been shown that 
cyclin dependent kinase enzyme 8 (CDK8) has been downregulated by certain miRNAs including 
miR-107 and miR-26b [45, 68]. The CDK8 enzyme has critical role in promoting cell cycle 
progression and cellular proliferation resulted in tumor growth and development. 
 
5. Conclusion 
Recent data indicate that multiple miRNAs are differentially expressed in breast cancer, 
and have critical roles in tumor cell proliferation, invasion, and metastasis (Table 1 and 2).  
As shown in figure 2, the overexpression of various miRNAs including miR-1229, miR-
125b, miR-3646, miR-29a, and miR-301 might contribute to aberrant activation of the Wnt/ β-
catenin signaling. The oncogenic activity of these miRNAs is mediated by targeting several tumor 
suppressors including GSK-3 β, APC and PTEN. Consistently, the Wnt signaling downstream 
target genes were upregulated resulted in tumor growth, metastasis and drug resistance in breast 
cancer patients. Conversely, the tumor suppressor miRNAs including miR-26b, miR-135, miR-
214, miR-216a, and miR-340 were found to have downregulated in breast cancer patients. These 
miRNAs were shown to have anti-tumor activity by inhibiting cancer cell proliferation through 
suppressing β-catenin. These data in combination with recent findings demonstrate that 
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uncontrolled activity of oncogenic Wnt/ β-catenin signaling is associated to poor prognosis and 
aggressive behavior in patients with breast cancer. 
In this review, we briefly discussed the previous data about the function of Wnt axis 
regulatory miRNAs involved in carcinogenesis of breast cancer. At present, there is a growing 
trend on targeting oncogenic miRNAs by certain inhibitors for anti-cancer approaches. 
Considering the oncogenic or anti-tumor function of miRNAs and their target genes, it has been 
proposed that miRNAs may be considered as new diagnostic and prognostic biomarkers for 
breast cancer. Therefore, regulating the oncogenic miRNAs by specific inhibitors or upregulation 
of anti-tumor miRNAs may be considered as novel miRNA‐based therapeutic strategies for 
management of breast cancer. 
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Figures 
 
Figure 1) Schematic model of the role of Wnt/β-catenin signaling regulatory microRNAs in breast 
cancer tumorigenesis. 
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Figure 2) The mechanisms of Wnt/ β-catenin signaling regulatory miRNAs in breast cancer 
carcinogenesis. 
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Table1. Oncogenic miRNAs regulate the pathogenesis of breast cancer by targeting the 
certain components of the Wnt/β-catenin signaling pathway. 
 
  
microRNA 
Molecular 
alteration 
Target Function Reference 
miR-1229 Upregulation GSK-3 β, APC, and ICAT Cellular proliferation 
Tan et al., 
2016 
miR-1301 Upregulation ICAT Cellular proliferation 
Lin et al., 
2016 
miR-125b Upregulation APC 
Cellular proliferation 
and metastasis 
Nie et al., 
2019 
miR-3646 Upregulation GSK-3 β Drug resistance 
Zhang et al., 
2016 
miR-29a Upregulation GSK-3 β Drug resistance 
Shen et al., 
2016 
miR-301 Upregulation PTEN 
Cellular proliferation 
and metastasis 
Ma et al., 
2014 
miR-374a Upregulation WIF1 and Wnt5a Tumor metastasis 
Cai et al., 
2013 
miR-638 Upregulation DACT3 Cellular proliferation 
Ren et al., 
2017 
miR-373 Upregulation β-catenin EMT 
De Chen et 
al., 2015 
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Table2. Tumor suppressor miRNAs regulate the pathogenesis of breast cancer by 
targeting the certain components of the Wnt/β-catenin signaling pathway. 
 
 
microRNA 
Molecular 
alteration 
Target Function Reference 
miR-26b Downregulation β-catenin 
Inhibits cellular 
proliferation 
Li et al., 2014a 
miR-135 Downregulation β-catenin 
Inhibits cellular 
proliferation 
Jiang et al., 
2019a 
miR-214 Downregulation β-catenin 
Inhibits cellular 
proliferation 
Yi et al., 2016 
miR-216a Downregulation β-catenin 
Inhibits cellular 
proliferation 
Xie et al., 2019 
miR-340 Downregulation β-catenin 
Inhibits cellular 
proliferation 
Mohammadi-
Yeganeh et al., 
2016 
miR-30a-5p Downregulation UBE3C 
Inhibits cellular 
proliferation and 
metastasis 
Xiong et al., 
2019 
miR-138 Downregulation CREPT 
Inhibits tumor growth 
and metastasis 
Liang et al., 
2017 
miR-449b-5p Downregulation CREPT 
Inhibits tumor growth 
and metastasis 
Jiang et al., 
2019 
miR-384 Downregulation ACVR1 
Inhibits tumor 
metastasis 
Wang et al., 
2018 
miR-30 Downregulation CTHRC1 
Inhibits cell invasion 
and metastasis 
Lai et al., 2017 
miR-140-5p Downregulation Wnt1 
Inhibits cellular 
proliferation 
Wu et al., 2019 
miR-224 Downregulation Frizzled 5 
Inhibits tumor 
progression 
Liu et al., 2016 
miR-1 Downregulation Frizzled 7 
Inhibits tumor 
progression 
Liu et al., 2015 
miR-100 Downregulation Frizzled 8 
Inhibits tumor 
progression 
Jiang et al., 
2016 
miR-27a Downregulation SFRPs 
Inhibits cell growth 
and invasion 
Kong et al., 
2017 
miR-107 Downregulation CDK8 
Inhibits cellular 
proliferation and 
metastasis 
Li et al., 2014 
miR-26b Downregulation CDK8 
Inhibits cellular 
proliferation and 
metastasis 
Li et al., 2014 
